Tag

Gp42

All articles tagged with #gp42

Antibody Breakthrough Blocks Epstein-Barr Virus in Mice, Could Aid Transplant Patients
science24 days ago

Antibody Breakthrough Blocks Epstein-Barr Virus in Mice, Could Aid Transplant Patients

Epstein-Barr virus (EBV) infects about 95% of adults and can persist for life, with links to cancers and other complications. A team from Fred Hutchinson Cancer Center and the University of Washington developed human-like antibodies targeting EBV surface proteins gp350 and gp42, isolating 10 candidates. In mice with humanized immune systems, one antibody provided protection against EBV, demonstrating a new approach to prevent infection and reactivation. The work could help immunosuppressed transplant patients by reducing EBV-related complications (PTLD), but human safety testing and clinical trials are still needed. Published in Cell Reports Medicine (2026).

Antibody therapy blocks Epstein-Barr virus, paving way for transplant-preventive treatment
health-and-medicine1 month ago

Antibody therapy blocks Epstein-Barr virus, paving way for transplant-preventive treatment

Researchers at Fred Hutchinson Cancer Center developed human-like monoclonal antibodies in a mouse model that block EBV from attaching to and entering B cells, with one gp42-targeting antibody fully preventing infection in humanized mice; the approach could become a preventive therapy to reduce EBV-related disease, including PTLD, in transplant patients, given that EBV infects about 95% of people worldwide. Next steps include safety testing and clinical trials.

Antibody Strategy Targets Epstein-Barr Virus to Shield Transplant Patients
science3 months ago

Antibody Strategy Targets Epstein-Barr Virus to Shield Transplant Patients

Fred Hutch researchers produced fully human monoclonal antibodies against EBV by targeting its gp350 and gp42 proteins. In humanized mice, one antibody completely prevented EBV infection and another offered partial protection, outlining a pathway to prevent EBV reactivation and PTLD in transplant patients. The team aims to advance safety testing in healthy volunteers followed by trials in immunocompromised individuals, with IP protection filed for the antibodies.